- Home
- ACRS vs TNYA Comparison
ACRS vs TNYA Comparison
Compare ACRS & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- TNYA
- Stock Information
- Founded
- ACRS 2012
- TNYA 2016
- Country
- ACRS United States
- TNYA United States
- Employees
- ACRS N/A
- TNYA N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- ACRS Health Care
- TNYA Health Care
- Exchange
- ACRS Nasdaq
- TNYA Nasdaq
- Market Cap
- ACRS 132.0M
- TNYA 119.2M
- IPO Year
- ACRS 2015
- TNYA 2021
- Fundamental
- Price
- ACRS $2.60
- TNYA $1.33
- Analyst Decision
- ACRS Strong Buy
- TNYA Strong Buy
- Analyst Count
- ACRS 5
- TNYA 4
- Target Price
- ACRS $11.00
- TNYA $17.33
- AVG Volume (30 Days)
- ACRS 956.3K
- TNYA 3.8M
- Earning Date
- ACRS 02-25-2025
- TNYA 03-17-2025
- Dividend Yield
- ACRS N/A
- TNYA N/A
- EPS Growth
- ACRS N/A
- TNYA N/A
- EPS
- ACRS N/A
- TNYA N/A
- Revenue
- ACRS $27,079,000.00
- TNYA N/A
- Revenue This Year
- ACRS N/A
- TNYA N/A
- Revenue Next Year
- ACRS N/A
- TNYA N/A
- P/E Ratio
- ACRS N/A
- TNYA N/A
- Revenue Growth
- ACRS 26.35
- TNYA N/A
- 52 Week Low
- ACRS $0.95
- TNYA $0.99
- 52 Week High
- ACRS $5.17
- TNYA $7.01
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- TNYA 36.06
- Support Level
- ACRS $2.31
- TNYA $1.43
- Resistance Level
- ACRS $2.64
- TNYA $1.63
- Average True Range (ATR)
- ACRS 0.16
- TNYA 0.12
- MACD
- ACRS 0.02
- TNYA 0.02
- Stochastic Oscillator
- ACRS 58.76
- TNYA 11.76
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.